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BACKGROUND: Recurrent pregnancy loss (RPL) occurs in 1–3% of all couples trying to conceive. No consensus exists regarding when to
perform testing for risk factors in couples with RPL. Some guidelines recommend testing if a patient has had two pregnancy losses whereas
others advise to test after three losses.
OBJECTIVE AND RATIONALE: The aim of this systematic review was to evaluate the current evidence on the prevalence of abnormal
test results for RPL amongst patients with two versus three or more pregnancy losses. We also aimed to contribute to the debate regarding
whether the investigations for RPL should take place after two or three or more pregnancy losses.
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SEARCH METHODS: Relevant studies were identified by a systematic search in OVID Medline and EMBASE from inception to March 2019.
A search for RPL was combined with a broad search for terms indicative of number of pregnancy losses, screening/testing for pregnancy loss
or the prevalence of known risk factors. Meta-analyses were performed in case of adequate clinical and statistical homogeneity. The quality of
the studies was assessed using the Newcastle-Ottawa scale.
OUTCOMES: From a total of 1985 identified publications, 21 were included in this systematic review and 19 were suitable for meta-analyses.
For uterine abnormalities (seven studies, odds ratio (OR) 1.00, 95% CI 0.79–1.27, I2 = 0%) and for antiphospholipid syndrome (three studies,
OR 1.04, 95% CI 0.86–1.25, I2 = 0%) we found low quality evidence for a lack of a difference in prevalence of abnormal test results between
couples with two versus three or more pregnancy losses. We found insufficient evidence of a difference in prevalence of abnormal test results
between couples with two versus three or more pregnancy losses for chromosomal abnormalities (10 studies, OR 0.78, 95% CI 0.55–1.10),
inherited thrombophilia (five studies) and thyroid disorders (two studies, OR 0.52, 95% CI: 0.06–4.56).
WIDER IMPLICATIONS: A difference in prevalence in uterine abnormalities and antiphospholipid syndrome is unlikely in women with
two versus three pregnancy losses. We cannot exclude a difference in prevalence of chromosomal abnormalities, inherited thrombophilia and
thyroid disorders following testing after two versus three pregnancy losses. The results of this systematic review may support investigations
after two pregnancy losses in couples with RPL, but it should be stressed that additional studies of the prognostic value of test results used in
the RPL population are urgently needed. An evidenced-based treatment is not currently available in the majority of cases when abnormal test
results are present.
Key words: recurrent pregnancy loss / investigations / screening tests / diagnostic strategy
Introduction
Recurrent pregnancy loss (RPL), defined as two pregnancy losses prior
to 20 weeks from the last menstrual period, occurs in 1–3% of all cou-
ples trying to conceive (ESHRE, 2017). Based on available data, there
is consensus that women should not undergo extensive evaluation
after a single first trimester or early second trimester pregnancy loss,
given that these are relatively common and sporadic events with only
a modestly increased risk of recurrence (Knudsen et al., 1991; Nybo
Andersen et al., 2000; Cohain et al., 2017). In prospective studies, the
risk of pregnancy loss increases with each loss from approximately 11%
amongst nulligravidae to approximately 40% after three or more losses
(Magnus et al., 2019).
Known risk factors for RPL are female age, previous pregnancy
losses, parental structural chromosomal abnormalities, uterine anoma-
lies, endocrine disturbances, antiphospholipid syndrome (APS) and
inherited thrombophilia (Jauniaux et al., 2006). Even after comprehen-
sive investigations, a cause for RPL is identified in fewer than 50%
of couples (Alijotas-Reig and Garrido-Gimenez, 2013). Consequently,
the majority of cases remain without a modifiable risk factor (Jaslow
et al., 2010). Only female age and number of prior pregnancy losses
have been consistently found to be prognostic factors for the major-
ity of patients (ESHRE, 2017). The tests currently performed are
often expensive, time-consuming and of uncertain prognostic value
(Christiansen et al., 2005). Furthermore, there is no consensus about
how many pregnancy losses couples should have experienced before
evaluation is warranted, leading to a variety of RPL definitions.
The Royal College of Obstetricians and Gynaecologists defines
RPL as three or more consecutive pregnancy losses (RCOG, 2011).
The American Society for Reproductive Medicine Practice Committee
defines RPL as two or more pregnancy losses confirmed by ultrasound
or histology, not necessarily consecutive (ASRM Practice Committee,
2012). The most recent RPL guideline from ESHRE set the definition
after a significant debate. It states that RPL could be considered after
the loss of two ormore pregnancies and stresses the importance of the
need for further scientific research, including epidemiological studies
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on the effect of various RPL definitions on diagnosis, prognosis and
treatment (ESHRE, 2017).
Although an evidence-based treatment is lacking for RPL, couples
value a plan for the next pregnancy (Musters et al., 2013). Before trying
to conceive, couples and clinicians attempt to find an explanation for
their pregnancy losses and a treatment that will prevent a recurrence,
especially in cases withmodifiable risk factors, such as thyroid disorders
and APS. This is why most guidelines advise investigations in RPL.
However, there is no consensus on when to perform investigations
for risk factors in couples with RPL.
There is a clear need for an evidence-based recommendation for
when to initiate investigations in RPL. As such, the goal of this study
was two-fold: first, to determine whether abnormal test results for
factors that are definite or probable risk factors for RPL occur with
equal frequency in womenwith two pregnancy losses versus those who
have had three or more pregnancy losses; second, to recommend if
investigations for RPL should take place after two or three or more
pregnancy losses.
Methods
Search strategy
This review followed the PRISMA guidelines for reporting systematic
reviews and meta-analyses (Fig. 1). A medical information specialist
( JL) performed a systematic search in OVID MEDLINE and OVID
EMBASE from inception to March 11th 2019, using both free text
and controlled terms (i.e. MeSH-terms in MEDLINE). A search for
RPL was combined with search filters for primary or secondary stud-
ies and a broad search for terms indicative of screening, obstetric
history, two versus three or more pregnancy losses and the rele-
vance/prevalence of known risk factors (Supplementary Table SI).
We cross-checked reference lists and citing articles of identified rel-
evant papers (in Web of Science) and adapted the search in case of
additional relevant studies. The bibliographic records retrieved were
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Figure 1 Study selection process for systematic review on the prevalence of abnormal evidence-based test result in women with
recurrent pregnancy loss.
imported and de-duplicated in ENDNOTE X7 © (Clarivate Analytics,
Boston, MA, USA). Authors were contacted for additional details
when required.
Selection criteria
Studies were selected if the prevalence of the abnormal test results
for RPL was reported. Only studies which compared women with two
pregnancy losses to women with three or more losses were included.
Based on current reviews of the literature, the following evidence-
based risk-factors for RPL were considered in this review: parental
structural chromosomal abnormalities, uterine anomalies, APS,
inherited thrombophilia and thyroid disorders. Results of parental
chromosomal analysis were considered abnormal if significant
rearrangements (e.g. balanced translocations and mosaics) were
present. Studies were selected when chromosome analyses were
performed with parental peripheral blood lymphocyte cultures.
Studies for uterine anomalies were selected if diagnostic testing was
performed by hysterosalpingography, hysteroscopy or sonohysterog-
raphy. Congenital abnormalities (e.g. arcuate uterus, septate uterus,
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bicornuate uterus and unicornuate uterus) were considered as uterine
anomalies.
APS was defined as the presence of thrombosis, pregnancy loss or
female morbidity and persistent circulating antiphospholipid antibodies
(aPL). aPLs (lupus anticoagulant, IgM anticardiolipin antibodies, IgG
anticardiolipin antibodies and beta-2 glycoprotein 1 antibodies) were
considered to be present if a test was positive on two occasions
>12 weeks apart (Miyakis et al., 2006).
Inherited thrombophilia was defined in four different sub-categories:
Factor V Leiden mutation, prothrombin gene mutation, protein S
deficiency and protein C deficiency. Factor V Leiden mutation was con-
sidered abnormal if there was a heterozygous or homozygous factor
V Leiden G1691A mutation found. Prothrombin gene mutation was
defined as heterozygous or homozygous mutations for the G20210A
prothrombin (factor II) gene. Functional protein C activity less than
70% and functional protein S activity less than 70% were considered
abnormal.
Thyroid disorders were defined as serum levels of thyroid-
stimulating hormone (TSH) <0.45 mU/L or TSH >4.5 mU/L with
an abnormal free thyroxine level with or without the presence of
thyroid peroxidase antibodies.
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Studies were excluded when the population examined or the diag-
nostic methods used were not accurately defined. Only publications in
English were considered in our selection.
Study selection
Studies were selected in a two-stage process using Covidence (Cov-
idence systematic review software, Veritas Health Innovation, Mel-
bourne, Australia). First, the titles and abstracts from the electronic
searches were examined independently by two reviewers (M.D. and
A.M.K.), and full manuscripts of all citations that met the predefined
selection criteria were obtained. Secondly, examinations of the full
manuscripts were carried out to decide on inclusion or exclusion
(M.D. and M.W.). In cases of duplicates, the most recent or the most
complete publication was used. Any disagreements about inclusion
were resolved by consensus or arbitration by a third reviewer (M.G.).
All selected papers were assessed for the following: study design,
adequate sampling, adequate description of population characteristics,
completeness of information in the data sets, and use of a validated
diagnostic method.
Data collection and extraction
Data collection was performed by two reviewers (M.D. and M.W.)
independently. Data were extracted based on patients’ characteristics,
study quality, inclusion and exclusion criteria, diagnostic tools used
and abnormal diagnostic test occurrence rates. Articles were judged
on scientific quality according to the Strengthening the Reporting of
Observational Studies in Epidemiology statement (White et al., 2015).
Levels of evidence were attributed according to the Oxford Cen-
tre for evidence-based medicine (Oxford Centre for Evidence-based
Medicine, 2009). The quality of each study was assessed with the
Newcastle-Ottawa Scale.
Statistical analysis
In order to reach a consistent presentation of the data, all individual
study results were translated into an odds ratio (OR) and 95% CI.
In case of adequate clinical and statistical homogeneity with the same
outcome measure, we performed meta-analyses using a random effect
model. Heterogeneity was assessed using the I2 statistic. We took an I2
measurement greater than 50% to indicate substantial heterogeneity.
To evaluate the possible presence of publication bias, a funnel plot
was made for outcomes with data of at least 10 studies (Cochrane
handbook). ReviewManager 5 (RevMan version 5.3. Copenhagen: The
Nordic Cochrane Centre, The Cochrane Collaboration, 2014) was
used to perform the meta-analyses.
Results
Of the 1958 publications identified, 21 publications met the inclusion
criteria, entailing 8301 couples with RPL. Reference checking of the
cited and citing articles of the included articles yielded no additional
relevant articles (Fig. 1 shows the PRISMA flowchart of the selection
process). Of the 21 articles included in this systematic review, 10
studies reported on chromosomal abnormalities (Michels et al., 1982;
Diedrich et al., 1983; FitzSimmons et al., 1983; Schwartz and Palmer,
1983; Sachs et al., 1985; Sider et al., 1988; Goddijn et al., 2004; Jaslow
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et al., 2010; Bashiri et al., 2012; Asgari et al., 2013), 7 studies reported
on testing for uterine anomalies (Weiss et al., 2005; Bohlmann et al.,
2010; Jaslow et al., 2010; Souza et al., 2011; Bashiri et al., 2012; Seckin
et al., 2012; Jaslow and Kutteh, 2013), 4 studies reported on testing for
antiphospholipid syndrome (Jaslow et al., 2010; Bashiri et al., 2012; van
den Boogaard et al., 2013; Guzel et al., 2015), 7 studies reported on
testing for inherited thrombophilia (Sotiriadis et al., 2007; Jaslow et al.,
2010; Bashiri et al., 2012; Karadeniz et al., 2012; Baumann et al., 2013;
Ali et al., 2014; Guzel et al., 2015) and 2 studies reported on testing for
thyroid disorders (Jaslow et al., 2010; Bashiri et al., 2012).
Quality of the studies
The characteristics of the included articles and quality assessment
are reported in Table I and Supplementary Table SII. The studies
were evidence-level IIb studies, i.e. cohort studies. Nineteen studies
presented appropriate data and could be included in meta-analyses.
Chromosomal abnormalities
A total of 10 studies (n=2498) reported on the difference in preva-
lence of parental structural chromosomal abnormalities in women with
two versus three or more pregnancy losses (Table I). When pooling
the studies, we found insufficient evidence for a difference in the
frequency of abnormal test results for parental structural chromosomal
abnormalities between women with two pregnancy losses and three
or more pregnancy losses (10 studies, OR 0.78, 95% CI: 0.55–1.10)
(Fig. 2).
When summarizing the individual proportions in the studies using
meta-analysis, we found a chromosomal abnormality prevalence of
5.3% (95% CI 2.8–7.8) after two pregnancy losses and 6.6% (95%
CI 3.8–9.3) after three pregnancy losses. These results indicate that
differences in prevalence of chromosomal abnormalities after two
or three pregnancy losses might be small, but that larger differences
cannot be fully excluded.
The funnel plot did not show an indication of publication bias
(Supplementary Fig. SI).
Uterine anomalies
Seven studies described the prevalence of uterine anomalies in women
with two pregnancy losses compared to three or more pregnancy
losses. Seven cohort studies (n=2343) were eligible for meta-analysis
and no significant difference in frequency of abnormal test results
for uterine anomalies could be detected between women with two
pregnancy losses and three or more pregnancy losses (seven studies,
OR 1.00, 95% CI 0.79–1.27) (Fig. 3). When summarizing the individual
proportions in the studies using meta-analysis, we found a prevalence
of 18% (95%CI 11–25) after two pregnancies and 17% (95%CI 11–23)
after three pregnancies. These results suggest that a clinically relevant
difference in prevalence is unlikely.
Antiphospholipid syndrome
Four included studies described the prevalence of APS in women with
two pregnancy losses compared to three or more pregnancy losses.
In a retrospective cohort study of 252 women with RPL, the levels
of anticardiolipin antibodies IgG and IgM were compared between
women with two versus three or more pregnancy losses. The test
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Table I Characteristics of the studies for chromosomal abnormalities, uterine anomalies, antiphospholipid syndrome,
thrombophilia and thyroid disorders identified in a systematic review of RPL
Author Year Study type Study
population
Prevalence 2
pregnancy losses
Prevalence ≥ 3
pregnancy losses
Outcome measures
.........................................................................................................................................................................................
Chromosomal abnormalities
Michels et al. 1982 Cohort 122 couples
2 PL n=48
≥ 3 PL n=74
Balanced
translocations 8.4%
(4/48)
Balanced
translocations 5.4%
(4/74)
Cytogenetic analysis from peripheral blood
lymphocyte cultures showed no significant
difference between 2 versus 3 or more
pregnancy losses.
Diedrich
et al.
1983 Cohort 136 couples
2 PL n=59
≥ 3 PL n=77
Abnormal
karyotype 10.2%
(6/59)
Abnormal
karyotype 11.9%
(9/77)
Chromosomal analysis from peripheral
blood lymphocyte cultures showed no
significant difference between 2 versus 3 or
more pregnancy losses.
FitzSimmons
et al.
1983 Cohort 645 couples
2 PL n=340
≥ 3PL n=305
Abnormal
karyotype 1.8%
(6/340)
Abnormal
karyotype 2.3%
(7/305)
Chromosomal analysis from peripheral
blood lymphocyte cultures showed no
significant difference between 2 versus 3 or
more pregnancy losses.
Schwartz
et al.
1983 Cohort 164 couples
2 PL n=71
≥ 3 PL n=93
Abnormal
karyotype 5.6%
(4/71)
Abnormal
karyotype 5.4%
(5/93)
Chromosomal analysis from peripheral
blood lymphocyte cultures showed no
significant difference between 2 versus 3 or
more pregnancy losses.
Sachs et al. 1985 Cohort 371 couples
2 PL n=182
≥ 3PL n=189
Abnormal
karyotype 9.3%
(17/182)
Abnormal
karyotype 9.5%
(18/189)
Chromosomal analysis from peripheral
blood lymphocyte cultures showed no
significant difference between 2 versus 3 or
more pregnancy losses.
Sider et al. 1988 Cohort 187 couples
2 PL n=99
≥ 3PL n=88
Abnormal
karyotype 3.0%
(3/99)
Abnormal
karyotype 6.8%
(6/88)
Chromosomal analysis from peripheral
blood lymphocyte cultures showed no
significant difference between 2 versus 3 or
more pregnancy losses.
Goddijn et al. 2004 Cohort 95 couples
2 PL n=55
≥ 3PL n=40
Abnormal
karyotype 32.7%
(18/55)
Abnormal
karyotype 37.5%
(15/40)
Chromosomal analysis from peripheral
blood lymphocyte cultures showed no
significant difference between 2 versus 3 or
more pregnancy losses.
Jaslow et al. 2010 Cohort 561 women
2 PL n=281
≥ 3PL n=280
Abnormal
karyotype 2.8%
(8/281)
Abnormal
karyotype 5.4%
(15/280)
Parental karyotypes showed no significant
difference between 2 versus 3 or more
pregnancy losses.
Bashiri et al. 2012 Cohort 114 couples
2 PL n=34
≥ 3 PL n=80
Abnormal
karyotype (0/34)
Abnormal
karyotype 4.0%
(4/80)
Parental genetics (significant
rearrangements (balanced translocations)
showed no significant difference between 2
versus 3 or more pregnancy losses.
Asgari et al. 2013 Cohort 140 couples
2 PL n=65
≥ 3PL n=75
Abnormal
karyotype 3.1%
(2/65)
Abnormal
karyotype 5.3%
(4/75)
Chromosomal analysis from peripheral
blood lymphocyte cultures showed no
significant difference between 2 versus 3 or
more pregnancy losses.
Uterine anomalies
Weiss et al. 2005 Cohort 165 women
2 PL n=67
≥ 3 PL n=98
22.4% (15/67) 17.3% (17/98) Identified by hysteroscopy. Considered
abnormal were congenital anomalies. No
difference in prevalence was found between
2 versus 3 or more pregnancy losses.
Bohlmann
et al.
2010 Cohort 206 women
2 PL n=78
≥ 3 PL n=119
9.2% (8/78) 16.8% (20/119) Identified by hysteroscopy. Considered
abnormal were congenital abnormalities.
No difference in prevalence was found
between 2 versus 3 or more pregnancy
losses.
Continued.
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Table I Continued.
Author Year Study type Study
population
Prevalence 2
pregnancy losses
Prevalence ≥ 3
pregnancy losses
Outcome measures
.........................................................................................................................................................................................
Jaslow et al. 2010 Cohort 875 women
2 PL n=401
≥ 3PL n=303
18.7% (75/401) 18.2% (55/303) Identified by hysterosalpingogram, hysteroscopy,
sonohysterography. Considered abnormal were
congenital anomalies, fibroids, polyps and septa,
Asherman’s syndrome adhesions. No difference
in prevalence was found between 2 versus 3 or
more pregnancy losses.
De Souza
et al.
2011 Cohort 66 women
2 PL n=23
≥ 3 PL n=43
17.3% (4/23) 11.6% (5/43) Identified by hysteroscopy. Considered abnormal
was congenital anomalies. No difference in
prevalence was found between 2 versus 3 or
more pregnancy losses.
Seckin et al. 2012 Cohort 220 women
2 PL n=151
≥ 3 PL n=69
26.5% (40/151) 30.4% (21/69) Diagnostic hysteroscopy.
Considered abnormal was congenital anomaly.
No difference in prevalence was found between
2 versus 3 or more pregnancy losses.
Bashiri et al. 2012 Cohort 114 women
2 PL n=38
≥ 3 PL n=78
31.6% (12/38) 23.1% (18/78) Hysteroscopy or 3D ultrasound. Considered
abnormal were septate uterus, unicornuate,
bicornuate, fibroids, polyps and Asherman’s
syndrome. No difference in prevalence was
found between 2 versus 3 or more pregnancy
losses.
Jaslow et al. 2013 Cohort 875 women
2 PL n=389
≥ 3 PL n=486
6.7% (26/389) 7.2% (35/486) Three dimensional sonohysterography.
Considered abnormal were congenital and
acquired abnormalities. No difference in
prevalence was found between 2 versus 3 or
more pregnancy losses.
Antiphospholipid syndrome
Jaslow et al. 2010 Cohort 729 women
2 PL n=409
≥ 3 PL n=320
15.6% (64/409) 13.1% (42/320) Lupus anticoagulant levels, Anticardiolipin IgG
and IgM were measured. No difference was
found between 2 versus 3 or more pregnancy
losses.
Bashiri et al. 2012 Cohort 120 women
2 PL n=39
≥ 3 PL n=81
10.3% (4/39) 13.6 (11/81) Lupus anticoagulant. No difference in prevalence
was found between 2 versus 3 or more
pregnancy losses.
Van den
Boogaard
et al.
2013 Cohort 2444 women
2 PL n=1526
≥ 3 PL n=918
17.4% (265/1526) 17.3% (159/918) Lupus anticoagulant levels, Anticardiolipin IgG
and IgM were measured. No difference was
found between 2 versus 3 or more pregnancy
losses.
Thrombophilia
Sotiriadis
et al.
2007 Cohort 99 women
2 PL n=56
≥ 3 PL n=43
2 PL= 56 3 PL= 43 There was no difference in the distribution of
Factor V Leiden, FII G20210A and MTHFR
between patients with 2 and 3 or more PLs.
Jaslow et al. 2010 Cohort 243 women Factor V Leiden 4.2%
(6/144)
Prothrombin gene
mutation 2.6% (3/115)
Protein S 3.5% (4/115)
Protein S 0.9% (1/115)
Factor V Leiden
8.1% (8/99)
Prothrombin gene
mutation (0/85)
Protein S 2.4%
(2/85)
Protein C (0/85)
Factor V Leiden mutation, prothrombin gene
mutation, protein C activity, protein S activity.
No difference was found between 2 versus 3 or
more pregnancy losses.
Bashiri et al. 2012 Cohort 120 women Factor V Leiden 4.8%
(1/21)
Prothrombin gene
mutation 13.6% (3/22)
Protein S 3.8% (1/26)
Protein C 7.7% (2/26)
Factor V Leiden
17.0% (8/47)
Prothrombin gene
mutation 4.5%
(2/44)
Protein S 13.6%
(8/59)
Protein C 8.2%
(5/61)
Factor V Leiden mutation, prothrombin gene
mutation, Protein S activity, Protein C activity.
No difference was found between 2 versus 3 or
more pregnancy losses.
Continued.
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Table I Continued.
Author Year Study type Study
population
Prevalence 2
pregnancy losses
Prevalence ≥ 3
pregnancy losses
Outcome measures
.........................................................................................................................................................................................
Karadeniz
et al.
2012 Cohort 108 women
2 PL n=42
≥ 3 PL n=66
Factor V Leiden
9.5% (4/42)
Prothrombin gene
mutation (0/42)
Protein S 16.6%
(7/42)
Protein C 16.6%
(7/42)
Factor V Leiden
7.5% (5/66)
Prothrombin gene
mutation 1.5%
(1/66)
Protein S 12.2%
(8/66)
Protein C 18.2%
(12/66)
Factor V Leiden mutation, prothrombin
gene mutation, Protein S activity, Protein C
activity. No difference was found between
2 versus 3 or more pregnancy losses.
Baumann
et al.
2013 Cohort 641 women
2 PL n=240
≥ 3 PL n=401
Factor V Leiden
8.3% (20/240)
Prothrombin gene
mutation 2.9%
(7/240)
Factor V Leiden
7.2% (29/401)
Prothrombin gene
mutation
3.5% (14/401)
Factor V Leiden, prothrombin gene
mutation. No difference was found
between 2 versus 3 or more pregnancy
losses.
Ali et al. 2014 Cohort 250 patients
2 PL n=125
≥ 3 PL n=125
Factor V Leiden
(0/23)
Prothrombin gene
mutation (0/175)
Protein S 1.1%
(2/175)
Protein C 1.1%
(2/175)
Factor V Leiden
11.5% (3/26)
Prothrombin gene
mutation 1.4%
(2/140)
Protein S 4.3%
(6/140)
Protein C 4.3%
(6/140)
Factor V Leiden mutation, prothrombin
gene mutation, protein C activity, protein S
activity. No difference was found between
2 versus 3 or more pregnancy losses.
Guzel et al. 2015 Cohort 252 women
2 PL n=72
≥ 3 PL n=180
Protein S deficiency
(84.18± 11.69)
Protein C
deficiency
(90.91± 23.35)
Protein S deficiency
(89.02± 22.47)
Protein C
deficiency
(106.57± 68.79)
Protein S deficiency and protein C
deficiency. No difference was found
between 2 versus 3 or more pregnancy
losses.
Thyroid disorders
Jaslow et al. 2010 Cohort 687 women
2 PL n=396
≥ 3 PL n=291
Abnormal TSH
8.0% (32/396)
Abnormal TSH
6.5% (19/291)
Serum levels of TSH< 0.45 mU/ml
or> 4.5 mU/ml
Bashiri et al. 2012 Cohort 118 women
2 PL n=38
≥ 3 PL n=80
Abnormal TSH
2.6% (1/38)
Abnormal TSH
16.3%(13/80)
Serum levels of TSH< 0.45 mU/ml
or> 4.5 mU/ml.
PL, pregnancy loss; TSH: thyroid-stimulating hormone, MTHFR: methylenetetrahydrofolate reductase.
results of women with two pregnancy losses (n=72) and three or
more (n=180) were not statistically significant different (anticardiolipin
IgG 7.62± 2.45 versus 10.01± 4.16GPLU/ml and IgM 4.76± 0.69
versus 4.22± 0.29MPLU/ml) (Guzel et al., 2015).
Three studies were appropriate to be included for meta-analysis.
No significant difference in frequency of abnormal results for APS was
found between women with two pregnancy losses and three or more
pregnancy losses (three studies, OR 1.04, 95% CI 0.86–1.25) (Fig. 4).
When summarizing the individual proportions in the studies using
meta-analysis, we found a prevalence of 16% (95% CI 14–18) after two
pregnancy losses and 15% (95%CI 12–18) after three pregnancy losses.
These results suggest that a clinically relevant difference in prevalence
is unlikely.
Inherited thrombophilia
Seven studies were identified which described the prevalence of inher-
ited thrombophilia in women with two pregnancy losses compared
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to three or more pregnancy losses. A cohort study compared the
prevalence of prothrombin gene mutation and Factor V Leiden muta-
tion in 99 women with two or more pregnancy losses with 102 healthy
controls. There was no difference in the distribution of Factor V Leiden
and prothrombin gene mutation between patients with two and three
or more pregnancy losses (Sotiriadis et al., 2007). In a retrospective
cohort study of 252 women with RPL, different diagnostic tests were
investigated. The results of cases with two pregnancy losses (n=72)
and more than two pregnancy losses(n=180) were not significantly
different for Protein S deficiency (84.18± 11.69 versus 89.02± 22.47)
and Protein C deficiency (90.91± 23.35 versus 106.57± 68.79)
(Guzel et al., 2015).
Five studies eligible for meta-analysis described the difference in
prevalence of factor V Leiden mutation (n= 1109). Meta-analysis
showed no significant difference in the prevalence of factor V Leiden
mutation between women with two pregnancy losses and three or
more pregnancy losses (five studies, OR 0.79, 95% CI 0.43–1.47)
(Fig. 5a). Five studies described the difference in prevalence of
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Figure 2 Forest plot of odds ratios of abnormal test results for parental chromosomal abnormalities in women with two
pregnancy losses or three or more pregnancy losses.
Figure 3 Forest plot of odds ratios of abnormal test results for uterine anomalies in women with two pregnancy losses or three
or more pregnancy losses.
Figure 4 Forest plot of odds ratios of abnormal test results for antiphospholipid syndrome in women with two pregnancy losses
or three or more pregnancy losses.
prothrombin gene mutation (n= 1330). A meta-analysis showed no
significant difference in frequency of prothrombin gene mutation
between women with two pregnancy losses and three or more
pregnancy losses (five studies, OR 1.08, 95% CI 0.44–2.62) (Fig. 5b).
Four studies described the difference in prevalence of protein S
deficiency (n= 708). A meta-analysis showed no significant difference
in frequency between women with two pregnancy losses and three
or more pregnancy losses (four studies, OR 0.72, 95% CI 0.27–1.94)
(Fig. 5c). Four studies described the difference in prevalence of protein
C deficiency (n= 710).Ameta-analysis showed no significant difference
in frequency between women with two pregnancy losses and three or
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
more pregnancy losses (four studies, OR 0.73, 95% CI 0.34–1.54)
(Fig. 5d).
Thyroid disorders
Two studies (n= 805) described the prevalence of thyroid disorders
in women with two pregnancy losses versus three or more. We
found insufficient evidence of a difference in frequency of abnormal
results for thyroid disorders (two studies, OR 0.52, 95% CI 0.06–4.56,
very low quality of evidence) (Fig. 6). There was substantial statistical
heterogeneity (I2 of 76%) between the studies; therefore, this finding
should be considered with care.
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Figure 5 Forest plot of odds ratio of abnormal test results for thrombophilia in women with two pregnancy losses or three or
more pregnancy losses. (a) Factor V Leiden mutation. (b) Prothrombin gene mutation. (c) Protein S deficiency. (d) Protein C deficiency.
Discussion
This systematic review investigated the available literature on the
prevalence of abnormal test results in women with RPL with different
numbers of previous pregnancy losses. Overall, we found no difference
in prevalence of abnormal test results for parental structural chromo-
some abnormalities, uterine anomalies, APS, inherited thrombophilia
and thyroid disorders in women with two pregnancy losses compared
with three or more pregnancy losses.
The most recent RPL guideline (ESHRE, 2017) recommends screen-
ing for antiphospholipid antibodies after two pregnancy losses. Thyroid
screening and assessment of uterine anatomy is recommended for RPL,
but no recommendation is given after how many pregnancy losses.
Parental karyotyping is not routinely recommended. As the chance
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of finding an abnormality is very low, it should only be considered
after an individual risk assessment (Franssen et al., 2005). As there
is a weak association between RPL and hereditary thrombophilia
and no available evidenced-based treatment, screening for hereditary
thrombophilia is not routinely recommended in couples with RPL
(ESHRE, 2017).
The results of this systematic reviewmay support investigations after
two pregnancy losses in couples with RPL, but it should be stressed
that additional studies of the prognostic value of test results used in
the RPL population are urgently needed. There is a paucity of effective
evidenced-based treatments for the majority of abnormal tests for
possible contributing factors for RPL. This is because many factors
have been associated with RPL but few meet accepted criteria for
causation. Therefore, testing should not be overvalued and the focus
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Figure 6 Forest plot of odds ratios of abnormal test results for thyroid disorders in women with two pregnancy losses or three
or more pregnancy losses.
should be on tailor-made supportive care in women with RPL. Couples
suffering from RPL need individualized management plans that include
appropriate support and, in this context, testing for associated factors
may help to reduce anxiety and manage expectations (Musters et al.,
2013).
In this systematic review, the quantity and quality of the evidence
on the comparison between the prevalence of abnormal test results
between groups were low. It follows that any conclusions and recom-
mendations should be drawn with care.
A methodological limitation of this study is the definition of the
study groups. As, on average, 15–20% of women with two losses
will experience a loss in the next pregnancy, some of the women in
the group with two pregnancy losses would be in the other group if
evaluated at a different time point. Comparing these groups at a certain
moment in time is a fictitious reality, and large studies of the prognostic
importance of test results would provide significant new insights into
the clinical relevance of diverse clinical tests.
There was no statistical heterogeneity across studies; this suggests
that the relative chance of pregnancy loss might be similar in different
countries, which could imply that our results are highly generalizable.
Two large cohort studies were present in all the meta-analyses and had
an important weight factor in the analysis (Jaslow et al., 2010; Bashiri
et al., 2012). The results of this systematic review were in line with
these two studies. A large systematic review on uterine anomalies
in women with RPL reported a prevalence of 10.9% (95% CI 3.6–
33.3) uterine anomalies in women with two and 15.4% (95% CI 10.3–
23) in women with three or more pregnancy losses, which was not
significantly different (P=0.572) (Chan et al., 2011).
In this systematic review, parental karyotyping was included, although
in the last few years, less karyotyping is performed in some countries.
In the work-up for couples with RPL, parental karyotyping of both
parents is expensive, and there is a very low chance of a live born
handicapped child with unbalanced chromosome abnormalities in the
unselected RPL population (Franssen et al., 2006; Barber et al., 2010).
These considerations have resulted in the recommendation not to
perform routine karyotyping of all couples with RPL, but rather after
an individual risk assessment (ESHRE, 2017). The treatment option
for chromosome abnormalities in couples with RPL consists of PGD.
However, limited evidence for PGD in couples with RPL shows no clear
benefit of treatment. Couples should be offered genetic counselling
and information on the treatment options (ESHRE, 2017).
We did not address genetic analysis of miscarriage tissue in this
systematic review. Since genetic analysis is not routinely recommended,
finding a fetal chromosomal abnormality does not necessarily rule
.
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out an underlying condition. However, it could be performed for
explanatory purposes (ESHRE, 2017).
It is important to note that the presence of a particular abnormal test
result in women with RPL does not prove causality for the pregnancy
losses. Female age and number of prior pregnancy losses have been
consistently found to be negative prognostic factors in numerous
cohort studies (Parazzini et al., 1988; Knudsen et al., 1991; Quenby
and Farquharson, 1993; Brigham et al., 1999; Bhattacharya et al., 2010;
Lund et al., 2012; Kolte et al., 2014; Greenberg et al., 2015; Kling et al.,
2016).
Female age at first live birth is almost 30 years in European pop-
ulations, and with an increasing female age, the risk of embryonic
aneuploidy increases. Therefore, embryonic aneuploidy will often be
the etiology behind RPL, especially in women older than 36 years
(Stephenson et al., 2002; Marquard et al., 2010). The decision on when
to start investigations should depend on female age and previous
pregnancy losses as well as other maternal conditions such as manifest
autoimmune or coagulative disease, family history and the results from
miscarriage tissue karyotyping, if performed (Bernardi et al., 2012). It
should also be the result of shared decision-making by the doctor and
couple whilst being compliant with available resources (ESHRE, 2017).
Customized diagnostic testing should be considered, where some test
can be performed and others omitted.
It should be noted that performing diagnostic testing after two
pregnancy losses means that a higher number of couples will have to
be investigated. Further studies are needed to assess the economic
implications of such a change in policy.
We propose that future research should focus on the design of a
dynamic prediction model for couples experiencing RPL. A dynamic
model has the advantage that it allows for adaptations to changes in
the underlying data over time (van Eekelen et al., 2017). In this model,
age, previous pregnancy losses and other risk factors for RPL, such as
APS, can be incorporated. If treatment possibilities are present for risk
factors (i.e. APS), correction should be applied. With this prediction
model, the chance of a live birth could be estimated more precisely. A
prediction model can also be used to give positive message to couples
suffering anxiety and depression following their pregnancy losses.
Conclusion
The prevalence of abnormal test results for RPL is low after two and
three or more pregnancy losses. A difference in prevalence in uterine
abnormalities and APS is unlikely in women with two versus three
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pregnancy losses. We cannot exclude a lower prevalence of chro-
mosomal abnormalities, inherited thrombophilia and thyroid disorders
following testing after two versus three pregnancy losses. The results of
this systematic review may support testing after two pregnancy losses
in couples with RPL, but it should be stressed that additional studies
of the prognostic value of test results used in the RPL population are
urgently needed. An evidenced-based treatment is not currently avail-
able in the majority of cases when abnormal test results are present.
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